Emerging therapeutic strategies, such as precision medicine approaches that target vulnerabilities in ERG driven pathways and DNA repair mechanisms, such as PARP inhibitors, may benefit a subset of these tumours, particularly those with additional mutations in DNA damage repair genes (104). This evidence concerns the gene ERG and neoplasm.